Sirolimus Market is Expected to Demonstrate a CAGR of 1.0% from 2019 to 2027
Posted by Sneha Talanakr on July 10th, 2019
Sirolimus: A Multi-action Promising Drug
Sirolimus could have a promising role in prophylaxis of rejection, treatment of refractory acute rejection, and chronic allograft dysfunction, as substantiated by various studies. Sirolimus is a new potent immunosuppressant whose profile could offer an advantage over other currently used drugs in view of its absence of intrinsic nephrotoxicity and efficacy as good as cyclosporin. Sirolimus could have both, a steroid sparing as well as a cyclosporin sparing effect.
Sirolimus may have a beneficial role in prophylaxis of rejection as well as treatment of refractory rejection. Sirolimus also has antifungal, antitumor, and anti-smooth muscle proliferative roles. The global sirolimus market was valued at US$ 285.00 Mn in 2018 and is projected to reach US$ 304.08 Mn by 2027, expanding at a CAGR of 1.0% from 2019 to 2027.
Promising Pipeline Opening New Market Opportunities
Global Sirolimus Market: Report Segmentation
Global Sirolimus Market: Competitive Insights
The global sirolimus market is highly fragmented due to the presence of a large number of players. Major players operating in the market include Pfizer, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Concept Medical, Inc., Stentys SA, Torrent Pharmaceuticals Ltd., Zydus Cadila, and Intas Pharmaceuticals Ltd.
Increase in trend of mergers & acquisitions and product approvals & launches in developing countries is expected to boost the global sirolimus market during the forecast period. Additionally, acquisitions drive growth in core business. Product approvals enable companies to enhance product portfolio globally.
The global sirolimus market has been segmented as follows:
Like it? Share it!
About the AuthorSneha Talanakr
Joined: April 22nd, 2019
Articles Posted: 279
More by this author